Oncology

Top news of the day from across the health care landscape.

Top news of the week in oncology, and cancer drug development.

Blocking the migration path of cancer cells in the blood could create new, effective treatments for cancers, such as lymphoma.

Discovery may help tumor suppression on a molecular level.

Advance in lung cancer therapy achieved on molecular level.

Bacterial differences were seen between tissue from patients with and without breast cancer.

Caregivers need to encourage patients fearful of life-saving tests for cancer.

Researchers plan to create an extensive cancer screening test that detects cancer blood biomarkers.

Drug to be evaluated combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

The FDA has granted breakthrough therapy designation to Novartis's ribociclib (LEE011).

Group of molecules may present target to slow tumor growth in prostate cancer.

Top news of the day from across the health care landscape.

Combination antibody therapy may lead to new melanoma treatment strategy.

Through physical evaluation, biphenotypic primary liver carcinoma could be misclassified.

The company will conduct a non-small cell lung cancer clinical trial with CV301 plus Opdivo.

Mutant KRAS gene may lead to new therapies for lung cancer.

Early treatment of ovarian cancer is vital to survival.

Specialty pharmacists aren't the only pharmacists who care for oncology patients.

Eli Lily’s clinical trial for abemaciclib will continue as planned.

Top news of the day from across the health care landscape.

Monoclonal antibody combination could offer less toxic acute lymphoblastic leukemia treatment.

Outdated measurements of cancer drug response could prevent some patients from receiving beneficial treatments.

Novel class of antitumor amphiphilic amines causes death in several cancer cell lines.

Hepatitis B can lead to liver cancer and cirrhosis.

Opdivo monotherapy for first-line lung cancer unable to meet primary endpoint of progression-free survival.

Athletes from a variety of sports dealt with the hardships of diseases treated by specialty pharmacy.

Updated criteria outlined by ASCO may lead to an increase in the number of breast cancers that test HER2-positive.

Top news of the day from across the health care landscape.